Bishop Kenneth Monroe: Prostate Cancer Survivor "Facing Uncertainty through Faith"
It was in the year 2000 when the Rev. Dr. Kenneth Monroe, then-pastor of the Metropolitan AME Zion Church, Hartford, CT noticed the need for more frequent bathroom breaks. Moreover, he realized that it was important to tell his doctor as soon as possible. He went for a physical and a prostate cancer screening which showed that his PSA count was 12.8. His doctor referred him to an urologist who ordered a prostate biopsy. The tissue was positive for cancer.
Tom Ficklin: Prostate Cancer Survivor "Remaining Calm in the Storm 'I Call it Thriving, Not Just Surviving'"
After a few years of slowly rising prostate specific antigen (PSA) counts, Tom Ficklin heard the words he was hoping he never would: “It’s time for a prostate biopsy.” Although the most important thing to Tom was his health and survival, he still wishes someone had discussed better pain management options with him before he had the biopsy. But when the results came back positive for cancer, his focus shifted to treatment options.
Weighing Cognitive Decline After Prostate Cancer Treatment
The October 17, 2019 Department of Internal Medicine’s inaugural The Second Century of Women at Yale: Emerging Leaders in Internal Medicine Medical Grand Rounds, “Cognitive Side Effects of Cancer Therapy,” was presented by Herta H. Chao, MD, PhD, associate professor of medicine (medical oncology).
Experimental Drug Shows Rapid Tumor Shrinkage in Advanced Bladder Cancer
A mid-stage treatment is showing significant promise in treating bladder cancer. An experimental drug developed by Astellas Pharma and Seattle Genetics rapidly shrank tumors in most patients, the companies announced this morning.Source: BioSpace
[VIDEO] Dr. Petrylak on Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
Daniel P. Petrylak, MD, professor of medicine and urology at Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancers, discusses the phase II EV-201 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.Source: OncLive TV
Las Vegas man first in the world to receive new prostate cancer drug
LAS VEGAS (KSNV) — Las Vegas resident Anthony Brasich is living on the cutting edge of cancer research. According to Comprehensive Cancer Centers, the 71-year old is the first person in the world to begin prostate cancer treatment with a drug called Arvinas. "I'm the first," said Brasich, "other than animals. Yes, I am the first human being to receive this drug."Source: News 3 Las Vegas
Meet Henry, a Patient who Prioritized His Health and Quality of Life When Facing Radiation Therapy for Prostate Cancer
In this testimonial video, Henry and his team at Yale Cancer Center share how radiation therapy along with SpaceOAR hydrogel was the right choice to get his prostate cancer treated and to protect his quality of life.Source: SpaceOAR Hydrogel
Advances in the Detection of Prostate Cancer
Aside from skin cancer, the most common site for cancer in American men is the prostate, with an estimated 160,000 new cases last year [ed.—2017]. Prostate cancer is also the third most deadly for American men, with more than 26,000 deaths in 2017. Yet the standard diagnostic method of searching for prostate tumors lags behind technologies used in other cancers. Researchers in the Yale School of Medicine’s Department of Urology are working to change that. They are developing imaging tools to give surgeons and radiologists a clearer picture of prostate cancers. Clearer images translate into more accurate diagnoses and more precise targeting of the tumors.
Management of Prostate Cancer
Known internationally for his work with clinical trials and research in the area of advanced prostate and bladder cancers, Dr. Petrylak will share his insights about the newest treatments for advanced cancers specific to men's health, including some of his research published in numerous medical journalsSource: Yale New Haven Health
Jimmy Carter May Benefit From Revolution in Cancer Immune Drugs
Harriet Kluger, an oncologist at the Yale Cancer Center and lead author on the study, said the trial has since expanded its enrollment, and additional patients have had responses -- including some whose brain tumors vanished completely. An updated report will be presented in a few months, she said. The fact that Carter’s tumors are small and were discovered early may help his prognosis, she said.Source: Bloomberg